Condition: Myopia · Myopia, Progressive · Sponsor: Laboratorios Sophia S.A de C.V.
Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in intraocular pressure, changes in the amplitude of accommodation, compared to placebo, as a treatment to delay the progression of myopia and axial ocular elongation in children.
This description comes directly from the study's public registry record.
Alejandra Sanchez-Rios, MD · 33 3001 4200 · alejandra.sanchez@sophia.com.mx
Always discuss trial participation with your own doctor first.
| Innovación Y Desarrollo En Ciencias de La Salud S de Rl de Cv | Mexico City, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06389110